tradingkey.logo

GSK plc

GSK
查看詳細走勢圖
60.230USD
+1.070+1.81%
收盤 02/06, 16:00美東報價延遲15分鐘
122.73B總市值
16.21本益比TTM

GSK plc

60.230
+1.070+1.81%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.81%

5天

+16.72%

1月

+18.98%

6月

+60.27%

今年開始到現在

+22.82%

1年

+67.12%

查看詳細走勢圖

TradingKey GSK plc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

GSK plc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名42/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為48.53。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

GSK plc評分

相關信息

行業排名
42 / 159
全市場排名
118 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

GSK plc亮點

亮點風險
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入43.02B美元
高分紅
公司屬於高分紅公司,最新股息支付率96.66%
穩定分紅
公司5年內持續分紅,最新股息支付率96.66%
估值合理
公司最新PE估值16.21,處於3年歷史合理位
機構減倉
最新機構持股391.69M股,環比減少5.30%
理查德·皮茲納持倉
明星投資者理查德·皮茲納持倉,最新持倉8.72K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.27

分析師目標

基於 10 分析師
買入
評級
48.528
目標均價
-15.21%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

GSK plc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

GSK plc簡介

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
公司代碼GSK
公司GSK plc
CEOWaterhouse (Deborah)
網址https://www.gsk.com/
KeyAI